Pfizer, BioNTech sign $1.95B vaccine distribution deal with the US

Pfizer and BioNTech inked a $1.95 billion deal with HHS and the U.S. Defense Department on July 22 to secure up to 600 million doses of BNT162, the two drugmakers' jointly-developed COVID-19 vaccine candidate.

Under the deal, the U.S. will receive 100 million doses of BNT162 and can obtain up to 500 million more doses. The U.S. plans to distribute the dosages among Americans at no charge.

The BNT162 program combines BioNTech's mRNA technology and Pfizer's manufacturing capabilities. The drugmakers expect to produce 100 million doses by the end of the year and more than 1.3 billion doses by the end of 2021, depending on the final dose selection from the candidate's clinical trial.

Pfizer and BioNTech are slated to begin a phase 2b/3 trial for safety and efficacy at the end of July, which could put them on a path to obtain regulatory review as early as October. 

More articles on pharmacy:
NIH updates remdesivir treatment guidelines
Growing number of polls find Americans hesitant about getting a future COVID-19 vaccine
Walgreens Boots Alliance appoints new chief technology officer

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers